Valda datamodeller

Du måste vara inloggad för att välja flera datamodeller, ladda ner dem eller analysera dem.

2 Sökresultat.
Relevans Bedömning Nya först Gamla först

Clinical activity of recMAGE-A3 + AS15 in patients with metastatic cutaneous melanoma NCT00942162 - Screening - Primary Tumor Characteristics; Regional Lymph Node Status; Tumor Sample (Annex Report 2 Final Annex Report 2 Final)

- 2021-09-20 - 1 Formulär, 4 Item-grupper, 27 Dataelement, 1 Språk
Item-grupper: Administrative, Primary Tumor Characteristics, Regional Lymph Node Status, Tumor Sample
Study ID: 111476 Clinical Study ID: 111476 Study Title: An open, single-arm trial to assess the clinical activity of recMAGE-A3 + AS15 in patients with unresectable MAGE-A3-positive metastatic cutaneous melanoma Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00942162 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Antigen-Specific Cancer Immunotherapeutic Study Indication: Melanoma

Clinical activity of recMAGE-A3 + AS15 in patients with metastatic cutaneous melanoma NCT00942162 - Screening - Primary Tumor Characteristics; Regional Lymph Node Status; Tumor Sample

- 2021-09-17 - 1 Formulär, 4 Item-grupper, 27 Dataelement, 1 Språk
Item-grupper: Administrative, Primary Tumor Characteristics, Regional Lymph Node Status, Tumor Sample
Study ID: 111476 Clinical Study ID: 111476 Study Title: An open, single-arm trial to assess the clinical activity of recMAGE-A3 + AS15 in patients with unresectable MAGE-A3-positive metastatic cutaneous melanoma Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00942162 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Antigen-Specific Cancer Immunotherapeutic Study Indication: Melanoma

Hjälp

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial